Immunotherapy Archives

News and Trends 9 Dec 2015

Squeezing Cells: A Revolutionary Cancer Drug Delivery Platform for €455M?

The MIT spin-off SQZ Biotech has an invention (Cell SQueeZe) which could make vector drug delivery in Cancer a thing of the past… Roche thinks so too, and has now acquired this small biotech for €455M upfront. MIT Professors Klavs Jensen, Robert Langer and PhD Student Armon Sharei were focused on developing a more effective system for […]

December 9, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 8 Dec 2015

Merck Pulls out of Plans to Commercialize Cancer Drug After it Fails in Two Phase III Trials

Threshold Pharmaceuticals in the US has failed at getting its hypoxia prodrug evofosfamide through phase III trials for two types of cancer, and as a result has lost Merck’s partnership on the program. Evofosfamide (TH-302) is an investigational hypoxia-activated prodrug discovered by Threshold Pharmaceuticals in Pennsylvania (US). The prodrug is activated only at very low […]

December 8, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 4 Dec 2015

Delenex Therapeutics, the Swiss Biotech developing new types of Therapeutic Antibodies

This week we leave the old city of Oxford and travel South East across the channel, through France and arrive at our destination, Zurich, Switzerland. This wonderful city is famous for its many churches (including the Minster), the largest church clock in Europe, found on St Peter’s and is the home of many celebrities including […]

December 4, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 3 Dec 2015

Meet the Company Fighting Autoimmune Diseases with a Novel Immunotherapy

BIO-Europe 2015 was a good opportunity for us to meet people who are playing a key role in the Biotech industry. I had the opportunity to meet Miguel Sieler, CEO of Neovacs, a company that can potentially be the first to develop a therapeutic vaccine for lupus patients! Neovacs is a French biotechnology company developing […]

December 3, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 30 Nov 2015

Cellectis’ CEO: “I’m just trying to be realistic, CAR-T is not THE miracle cure for Cancer”

CAR-T is solidifying in everybody’s mind as the next revolution in Cancer treatment. But there is still a lot to do…That’s basically what came out from my discussion with André Choulika, the CEO of the French CAR-T miracle Cellectis. Cellectis is probably the most successful Biotech in France. It was founded in 1999 by Choulika […]

November 30, 2015 - 5 minutesmins - By Philip Hemme

News and Trends 27 Nov 2015

Biotech of the week: PsiOxus, “non-traditional” Immuno-oncology from Oxford

This week we leave Ireland and head South-East across the Irish Sea where we arrive at the ancient city of Oxford, our location of interest. ‘The city of dreaming spires’ is known for it’s world famous university, the Shark House (if you don’t know it, have a search, you won’t regret it :p) and the location for […]

November 27, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 17 Nov 2015

What will Happen now the Microbiome Hype has Broken into the Immuno-Oncology Field?

The Microbiome and Immuno-Oncology fields are hugely trendy in the Biotech Industry – and now a marriage between the two has finally occurred… The Microbiome field is still very new, with the launch of the US Human Microbiome Project just happening in 2008. Nonetheless, some start-ups are moving fast up the microbiome ranks, as well […]

November 17, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 9 Nov 2015

Leading TCR Immuno-oncology Biotech shows Promising Results against Cancer

Cell-based Immune-oncology therapies continue to deliver amazing results. After Cellectis wondersaving from last week, Oxford’s Adaptimmune has some surprisingly good results too. Adaptimmune is a British, Oxford-based immuno-oncolgy company. It held a massive IPO last year, raising up to €150M on the NASDAQ, and its CEO was interviewed by BIO (video here) where he seemed […]

November 9, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 4 Nov 2015

€1.37Bn Deal for Sanofi with Germany’s Fastest Growing mRNA Cancer Biotech

Sanofi is now the latest Biotech lining up to partner with BioNTech from Mainz (Germany), for license of their mRNA Immuno-oncology platform in a€1.37Bn long-term development deal. Novel mRNA targets in Immuno-onology is a top-shelf cancer R&D area, with Germany’s CureVac also attracting another €100M yesterday for their mRNA platform (which targets lung and prostate […]

November 4, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 3 Nov 2015

Exclusive from BIO-Europe 2015: Interview of Peter Llewellyn-Davies, CFO at Medigene, Munich-based Immunotherapy Biotech

This is the third interview we publish from BIO (yes, we are working hard). It comes after the interview of Simon Moroney, CEO of MorphoSys and Jane Dancer, CBO of F-star. Medigene is another big/famous Biotech company of Munich, Germany. It was founded over 20 years ago and is now specialised in cell-based therapies. It counts […]

November 3, 2015 - 1 minutemin - By Philip Hemme

News and Trends 2 Nov 2015

Exclusive from BIO-Europe 2015: Interview of Simon Moroney, CEO of leading German Biotech MorphoSys

BIO-Europe is also a great opportunity to meet with top people from EU’s Biotech ecosystem. I had the chance to interview Simon Moroney, the CEO and one of the founders of MorphoSys (part of our top 9 EU-based billion euros Biotechs). The Munich-based company was founded in 1992 and now counts +-350 employees for a market […]

November 2, 2015 - 1 minutemin - By Philip Hemme

News and Trends 26 Oct 2015

The First Ever Oncolytic Immunotherapy is Set to Reach the European Market

Amgen is now months away from a European approval with Imlygic (also known as T-VEC) – the first oncolytic immunotherapy for advanced melanoma. The Committee for Medicinal Products for Human Use (CHMP) and the scientific committee of the European Medicines Agency (EMA), have reacted positively. Melanoma is a type of skin cancer that is characterized by the uncontrolled growth of melanocytes, […]

October 26, 2015 - 2 minutesmins - By Julie Lellouche

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Immunotherapy

Squeezing Cells: A Revolutionary Cancer Drug Delivery Platform for €455M?

Merck Pulls out of Plans to Commercialize Cancer Drug After it Fails in Two Phase III Trials

Delenex Therapeutics, the Swiss Biotech developing new types of Therapeutic Antibodies

Meet the Company Fighting Autoimmune Diseases with a Novel Immunotherapy

Cellectis’ CEO: “I’m just trying to be realistic, CAR-T is not THE miracle cure for Cancer”

Biotech of the week: PsiOxus, “non-traditional” Immuno-oncology from Oxford

What will Happen now the Microbiome Hype has Broken into the Immuno-Oncology Field?

Leading TCR Immuno-oncology Biotech shows Promising Results against Cancer

€1.37Bn Deal for Sanofi with Germany’s Fastest Growing mRNA Cancer Biotech

Exclusive from BIO-Europe 2015: Interview of Peter Llewellyn-Davies, CFO at Medigene, Munich-based Immunotherapy Biotech

Exclusive from BIO-Europe 2015: Interview of Simon Moroney, CEO of leading German Biotech MorphoSys

The First Ever Oncolytic Immunotherapy is Set to Reach the European Market

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!